Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: Mama Bear who wrote (938)	6/9/2000 4:34:00 PM
From: david james	Read Replies (2) \| Respond to of 1298

Over $30 afterhours. quotes.nasdaq-amex.com TKTX halted and up 35%. AMGN down. Looks like the trial is looking good for TKTX - and CEGE gets royalties since they use CEGE technology. $4 billion in Epogen sales is at stake in that trial. cellgenesys.com The license agreement with Aventis Pharmaceuticals provides access to Cell Genesys' gene activation intellectual property for gene-activated EPO and a second undisclosed protein. In exchange, Cell Genesys may receive up to $26 million in milestone payments and fees in addition to royalties on potential future sales of these two gene-activated products. To date, Cell Genesys has received over $15 million from the license agreement with Aventis Pharmaceuticals and a total of more than $23 million from its entire licensing program for gene activation technology. In late 1998, Cell Genesys received a milestone payment of $2 million as a result of the initiation of a Phase III clinical trial for anemia using gene-activated EPO, which Aventis Pharmaceuticals is developing in collaboration with Transkaryotic Therapies, Inc. (Nasdaq: TKTX).